News
-
United Therapeutics has announced the initiation of the 52-week TETON PPF trial, which will evaluate the efficacy of Tyvaso treprostinil inhalation solution in almost 700 patients with progressive pulmonary fibrosis (PPF). The company said that the… Read more . . .
-
According to Syqe Medical, Australia’s Therapeutic Goods Administration (TGA) has approved the company’s SyqeAir cannabis inhaler, which includes 60 metered doses of milled cannabis flowers. The cartridge-based inhaler will now appear in the Australian Register… Read more . . .
-
Transpire Bio, which launched in 2022 to develop inhaled therapeutics for both local and systemic delivery, has officially opened its new headquarters and research facility in Weston, FL, USA. Shortly after launching, the company announced… Read more . . .
-
According to MannKind Corporation, the United States Patent and Trademark Office (USPTO) has issued US patent No. 11,793,808 (“Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising Them”), which covers… Read more . . .
-
Researchers at the University of Sydney have been awarded $687,000 by the FDA to support a project titled, “Development of a laser-based testing platform for generic dry powder inhaler DPI evaluation and in-silico model validation,”… Read more . . .
-
According to AstraZeneca, the FDA has accepted for review the company’s supplemental biologics license application (sBLA) for self-administration of FluMist Quadrivalent nasal spray vaccine against influenza. AstraZeneca says that it expects a PDUFA date in the… Read more . . .
-
Researchers at the United States National Aeronautics and Space Administration (NASA) will lead 2 Phase 2 studies of Defender Pharmaceuticals’ DPI-386 scopolamine nasal gel for the prevention of motion sickness induced by sudden changes in… Read more . . .
-
Milestone Pharmaceuticals said that it has submitted an NDA for its etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) and that the FDA has conditionally approved the proposed trade name “Cardamyst.” The company… Read more . . .
-
Beckley Psytech has announced the initiation of a Phase 2b trial of BPL-003 intranasal synthetic 5-MeO-DMT (mebufotenin) in people with moderate-to-severe treatment resistant depression. In February 2023, the company announced that the FDA approved an IND… Read more . . .
-
Qnovia (formerly Respira Technologies) has announced a partnership with researchers at the University of Virginia (UVA) for the development of two new antimicrobial peptides for delivery via the company’s RespiRx vibrating mesh nebulizer technology. The… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden